DALI : Vitamin D and lifestyle intervention for gestational diabetes mellitus (GDM) prevention : an European multicentre, randomised trial - study protocol

Judith G. M. Jelsma, Mireille N. M. van Poppel, Sander Galjaard, Gernot Desoye, Rosa Corcoy, Roland Devlieger, Andre van Assche, Dirk Timmerman, Goele Jans, Jurgen Harreiter, Alexandra Kautzky-Willer, Peter Damm, Elisabeth R. Mathiesen, Dorte M. Jensen, Liselotte Andersen, Fidelma Dunne, Annunziata Lapolla, Graziano Di Cianni, Alessandra Bertolotto, David Simmons

    Research output: Contribution to journalArticlepeer-review

    96 Citations (Scopus)

    Abstract

    Background: Gestational diabetes mellitus (GDM) is an increasing problem world-wide. Lifestyle interventions and/or vitamin D supplementation might help prevent GDM in some women. Methods/design: Pregnant women at risk of GDM (BMI≥29 (kg/m2)) from 9 European countries will be invited to participate and consent obtained before 19+6 weeks of gestation. After giving informed consent, women without GDM will be included (based on IADPSG criteria: fasting glucose<5.1mmol; 1 hour glucose <10.0 mmol; 2 hour glucose <8.5 mmol) and randomized to one of the 8 intervention arms using a 2×(2×2) factorial design: (1) healthy eating (HE), 2) physical activity (PA), 3) HE+PA, 4) control, 5) HE+PA+vitamin D, 6) HE+PA+placebo, 7) vitamin D alone, 8) placebo alone), pre-stratified for each site. In total, 880 women will be included with 110 women allocated to each arm. Between entry and 35 weeks of gestation, women allocated to a lifestyle intervention will receive 5 face-to-face, and 4 telephone coaching sessions, based on the principles of motivational interviewing. The lifestyle intervention includes a discussion about the risks of GDM, a weight gain target <5kg and either 7 healthy eating 'messages' and/or 5 physical activity 'messages' depending on randomization. Fidelity is monitored by the use of a personal digital assistance (PDA) system. Participants randomized to the vitamin D intervention receive either 1600 IU vitamin D or placebo for daily intake until delivery. Data is collected at baseline measurement, at 24-28 weeks, 35-37 weeks of gestation and after delivery. Primary outcome measures are gestational weight gain, fasting glucose and insulin sensitivity, with a range of obstetric secondary outcome measures including birth weight. Discussion: DALI is a unique Europe-wide randomised controlled trial, which will gain insight into preventive measures against the development of GDM in overweight and obese women.
    Original languageEnglish
    Article number142
    Number of pages16
    JournalBMC Pregnancy and Childbirth
    Volume13
    DOIs
    Publication statusPublished - 2013

    Open Access - Access Right Statement

    © 2013 Jelsma et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

    Keywords

    • diabetes in pregnancy
    • obesity
    • pregnancy
    • prevention
    • vitamin D

    Fingerprint

    Dive into the research topics of 'DALI : Vitamin D and lifestyle intervention for gestational diabetes mellitus (GDM) prevention : an European multicentre, randomised trial - study protocol'. Together they form a unique fingerprint.

    Cite this